Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy
- 10 September 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (26), 4137-4145
- https://doi.org/10.1200/jco.2007.11.5303
Abstract
Limited-stage (LS) small-cell lung cancer (SCLC) remains a therapeutic challenge to medical and radiation oncologists. The treatment of LS-SCLC has evolved significantly over the last two decades with combined-modality therapy now the standard of care. The addition of thoracic radiotherapy (TRT) to standard chemotherapy has led to improvements in long-term survival in this population. However, many questions remain about the optimal way to deliver chemoradiotherapy. In a landmark trial, twice-daily TRT to a dose of 45 Gy increased 5-year survival by 10% compared with once-daily TRT administered to the same dose. This suggests that more intensive TRT regimens may lead to further survival gains, assuming they can be delivered safely in this setting. Strategies currently under investigation include higher total daily doses delivered once daily or novel concurrent boost techniques allowing more intensive treatments over shorter periods of time. Several trials and meta-analyses have evaluated the timing of TRT with chemotherapy, with the weight of evidence suggesting that early and concurrent TRT with chemotherapy is optimal. Novel cytotoxic chemotherapy combinations have failed thus far to provide an advantage over standard etoposide-cisplatin combinations. Prophylactic cranial irradiation in near or complete responders to induction chemoradiotherapy has also been shown to improve long-term survival rates. LS-SCLC has been a model cancer in terms of the potential benefit of combined chemoradiotherapy strategies in improving patient outcomes.This publication has 82 references indexed in Scilit:
- Decision Analysis for Prophylactic Cranial Irradiation for Patients With Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Critical review of PET-CT for radiotherapy planning in lung cancerCritical Reviews in Oncology/Hematology, 2005
- A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancerInvestigational New Drugs, 2005
- Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903Clinical Cancer Research, 2005
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancerLung Cancer, 2004
- Radiotherapy Patterns of Care Study in Lung CarcinomaJournal of Clinical Oncology, 2003
- The Outcome of Combined-Modality Therapy for Stage III Non–Small-Cell Lung Cancer in the ElderlyJournal of Clinical Oncology, 2003
- A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancerBone Marrow Transplantation, 2000
- The linear-quadratic formula and progress in fractionated radiotherapyThe British Journal of Radiology, 1989
- Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the LungThe New England Journal of Medicine, 1987